image credit: Freepik

Roche gambles $125M on a sliding biotech’s cancer drug

June 2, 2022


The most immediate effect of the deal is a much-needed infusion of funds for Repare, which went public in 2020 at a price of $20 a share. The company’s stock soared above $42 in early 2021, only to plummet as investors turned sour on biotech startups.

Repare ended the first quarter with $312 million in cash, cash equivalents and marketable securities. With the Roche deal in hand, company executives told investors the biotech’s cash runway will be extended into 2026.

Read More on Biopharma Dive